

UC Davis

UC Davis Previously Published Works

Title

Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas

Permalink

<https://escholarship.org/uc/item/1w55t3g7>

Journal

International Journal of Molecular Sciences, 25(6)

ISSN

1661-6596

Authors

Cruz, Sylvia M
Iranpur, Khurshid R
Judge, Sean J
[et al.](#)

Publication Date

2024

DOI

10.3390/ijms25063351

Peer reviewed



Article

Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas

Sylvia M. Cruz ^{1,†} , Khurshid R. Iranpur ^{1,†}, Sean J. Judge ¹, Erik Ames ², Ian R. Sturgill ³, Lauren E. Farley ¹, Morgan A. Darrow ⁴, Jiwon Sarah Crowley ¹, Arta M. Monjazebe ⁵, William J. Murphy ⁶ and Robert J. Canter ^{1,*}

¹ Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA

² Department of Pathology, Stanford University, Stanford, CA 94305, USA

³ Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

⁴ Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA

⁵ Department of Radiation Oncology, University of California Davis, Sacramento, CA 95817, USA

⁶ Department of Dermatology, University of California Davis, Sacramento, CA 95817, USA; wjmurphy@ucdavis.edu

* Correspondence: rjcanter@ucdavis.edu

† These authors contributed equally to this work.

Abstract: The cancer stem cell (CSC) hypothesis postulates that heterogeneous human cancers harbor a population of stem-like cells which are resistant to cytotoxic therapies, thus providing a reservoir of relapse following conventional therapies like chemotherapy and radiation (RT). CSCs have been observed in multiple human cancers, and their presence has been correlated with worse clinical outcomes. Here, we sought to evaluate the impact of drug dosing of the multi-tyrosine kinase inhibitor, sorafenib, on CSC and non-CSCs in soft tissue sarcoma (STS) models, hypothesizing differential effects of sorafenib based on dose and target cell population. In vitro, human cancer cell lines and primary STS from surgical specimens were exposed to escalating doses of sorafenib to determine cell viability and expression of CSC marker aldehyde dehydrogenase (ALDH). In vivo, ALDH^{bright} CSCs were isolated, exposed to sorafenib, and xenograft growth and survival analyses were performed. We observed that sarcoma CSCs appear to paradoxically respond to the tyrosine kinase inhibitor sorafenib at low doses with increased proliferation and stem-like function of CSCs, whereas anti-viability effects dominated at higher doses. Importantly, STS patients receiving neoadjuvant sorafenib and RT on a clinical trial (NCT00864032) showed increased CSCs post therapy, and higher ALDH scores post therapy were associated with worse metastasis-free survival. These data suggest that low-dose sorafenib may promote the CSC phenotype in STS with clinically significant effects, including increased tumor growth and higher rates of metastasis formation in sarcoma patients.

Keywords: cancer stem cells; sorafenib; ALDH; sarcoma; survival



Citation: Cruz, S.M.; Iranpur, K.R.; Judge, S.J.; Ames, E.; Sturgill, I.R.; Farley, L.E.; Darrow, M.A.; Crowley, J.S.; Monjazebe, A.M.; Murphy, W.J.; et al. Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas. *Int. J. Mol. Sci.* **2024**, *25*, 3351. <https://doi.org/10.3390/ijms25063351>

Academic Editor: Anthony Lemarié

Received: 4 February 2024

Revised: 14 March 2024

Accepted: 14 March 2024

Published: 15 March 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cancer stem cells (CSCs) have been identified as a clinically relevant subpopulation within multiple cancers in both pre-clinical models and patient samples [1–3]. CSCs are characterized as quiescent cells within heterogeneous tumors with their dormancy promoting resistance to standard cytotoxic treatments such as chemotherapy and radiotherapy (RT) [1,4–6]. The presence of CSCs has been associated with worse clinical outcomes across multiple cancer types [6–9]. Although the etiology of CSCs remains controversial and debate continues regarding the origin of CSCs, both genetic and epigenetic mechanisms have been implicated in the phenotype and function of stem-like tumor cells. These factors make them distinct from bulk tumor cells and clinically relevant as a sub-population [6,8,10].

Moreover, CSCs are an important target in cancer therapy due to their ability to repopulate and promote relapse in breast, sarcoma, pancreas, renal, and other cancers [11–14]. These stem-like properties, such as self-renewal, differentiation potential, and upregulation of key signaling pathways (such as Notch, Hedgehog, Hippo-YAP) have been linked with repopulation of tumors post treatment [15–18]. This suggests that targeting CSCs could significantly improve clinical outcomes for cancer patients.

We previously demonstrated that tyrosine kinase inhibitors (TKIs), especially sorafenib, are associated with CSC enrichment because of their depleting effects on bulk tumor cells [19–21]. Sorafenib is a TKI that has shown promise as an anti-neoplastic inhibitor of B-Raf and Raf1/c-Raf signaling pathways [22]. Sorafenib is FDA-approved for renal cell and hepatocellular carcinoma based on improvements in both progression-free and overall survival [23,24]. We previously evaluated sorafenib with RT in a phase I trial of neoadjuvant therapy for soft tissue sarcoma (STS), establishing a maximum tolerated dose [25]. However, given our pre-clinical data showing differential effects of sorafenib on CSC and non-CSC populations, we sought to determine the potential pre-clinical and clinical impact of these CSC changes mediated by sorafenib on outcomes. We used pazopanib, a clinically approved STS treatment, as a relevant control [26]. We hypothesized that CSCs respond differently to pharmacologic stresses given their different genetic and epigenetic compositions. We sought to evaluate the impact of sorafenib on CSC proliferation, CSC function, and clinical outcomes using multiple in vitro and in vivo models including primary STS specimens from surgery and patients receiving neoadjuvant sorafenib and RT on a clinical trial (NCT00864032).

2. Results

2.1. Sorafenib Stimulates CSC Expansion In Vitro at Low Doses in Sarcoma Cell Lines with Anti-Viability Effects at Higher Doses

Although the exact origin of CSCs remains controversial, the CSC phenotype has been reproducibly identified by multiple experimental techniques [27–29]. In STS, high expression of the enzyme aldehyde dehydrogenase (so-called ALDH^{bright}) has been linked with the CSC phenotype while other markers (CD24, CD44, and CD133) have shown mixed results [30–33]. Given the plasticity associated with CSC markers [34,35], we sought to revalidate the functional properties of ALDH^{bright} sarcoma CSCs with the prototypical CSC colony outgrowth assay. Using sorted ALDH^{bright} cells from Ewing's sarcoma cell line A673, we assessed colony forming units (CFUs) and observed significantly higher numbers of colonies among the ALDH^{bright} versus ALDH^{dim} populations in a dose-dependent fashion (Figure S1A–C).

We then assessed the effect of sorafenib on CSC and non-CSC populations in vitro. A673, SK-LMS, and SW982 cell lines were exposed to increasing doses of sorafenib. We observed a consistent cytotoxic effect of sorafenib at sorafenib doses of 8 μ M and higher (Figure 1A–C). However, there was a significant increase in CSCs at doses ranging from 2 to 4 μ M as observed in the absolute number of ALDH^{bright} cells (Figure 1D–F). At doses above 8 μ M, this increase in ALDH^{bright} absolute cell numbers was reversed, and the number of ALDH^{bright} cells declined significantly ($p < 0.001$). Additionally, we observed no differences in ALDH^{bright} cell numbers over the range of doses for pazopanib (Figure 1D–F), consistent with the primarily anti-angiogenic, non-cytotoxic effects of this agent [26]. Representative flow cytometry is shown in Figure 1G,H. Importantly, as shown in Figure 1I,J, ALDH^{bright} cells increased in both numbers and percentages at a dose of 4 μ M sorafenib, whereas ALDH^{bright} cell numbers decreased at high-dose sorafenib (32 μ M), but the percentage of ALDH^{bright} cells increased, consistent with differential effects of the drug on bright and dim populations at the different doses.




Figure 1. Sorafenib treatment is associated with increased cancer stem cells at low doses, but cytotoxic effects at higher doses in sarcoma cells in vitro. (A–C) A673 Ewing’s sarcoma cells, SK-LMS leiomyosarcoma cells, and SW982 synovial sarcoma cells were cultured with increasing doses of sorafenib and pazopanib. Absolute numbers of viable cells were measured by flow cytometry using 7-AAD to distinguish viable and non-viable cells. (D–F) A673 Ewing’s sarcoma cells, SK-LMS leiomyosarcoma cells, and SW982 synovial sarcoma cells were cultured with increasing doses of sorafenib and pazopanib, and ALDH^{bright} cells were measured by flow cytometry using the ALDEFLUOR™ assay. (G) Representative flow cytometry staining of A673 ALDH^{bright} cells comparing no treatment (left) to 4 μM sorafenib treatment (right). (H) Representative flow cytometry staining of SK-LMS ALDH^{bright} cells comparing no treatment (left) to 4 μM sorafenib treatment (right). (I) Cell numbers of ALDH^{bright} and ALDH^{dim} cells within untreated (0 μM), low-dose sorafenib (4 μM), and high-dose sorafenib (16 μM) groups were measured by flow cytometry using the ALDEFLUOR™ assay. (J) Percentage of ALDH^{bright} and ALDH^{dim} cells within untreated (0 μM), low-dose sorafenib (4 μM), and high-dose sorafenib (16 μM) groups were measured by flow cytometry using the ALDEFLUOR™ assay. All experiments were performed in triplicate. ** $p < 0.01$, *** $p < 0.001$, **** $p \leq 0.0001$ via one-way ANOVA with Tukey’s test.

Since drug dosing in patients frequently involves long-term, continuous exposure, we tested the effect of longer-term exposure to sorafenib on the viability and frequency of both CSC and non-CSC populations in vitro. As shown in Figure S1D, A673 cells were continuously cultured in the presence of 4 μM sorafenib which was refreshed every 3–4 days for 14 days. After this 14-day period, cells were trypsinized, washed, and replated for 48 h sorafenib exposure in vitro. Cells grown in standard culture conditions (without chronic

sorafenib exposure) reproduced a similar pattern of an approximate doubling of numbers of ALDH^{bright} cells at low doses from 2– to 4 μM , which was statistically significant ($p \leq 0.001$, Figure S1E). Similarly, ALDH^{bright} A673 cells cultured under standard conditions and then acutely exposed to sorafenib again significantly declined in numbers of ALDH^{bright} cells at doses $\geq 8 \mu\text{M}$ ($p < 0.001$). Although the cells chronically exposed to sorafenib had a less exaggerated increase in ALDH^{bright} numbers after acute sorafenib exposure, this increase in ALDH^{bright} cell numbers was statistically significant at low doses while anti-viability effects were observed in both CSCs and non-CSCs at doses $\geq 8 \mu\text{M}$ (Figure S1F). Taken together, these data suggest that low-dose sorafenib leads to an increase of ALDH^{bright} CSCs in sarcoma lines, which is modulated at higher doses due to cytotoxic effects of sorafenib.

2.2. Low-Dose Sorafenib Stimulates In Vitro Proliferation of CSCs across Multiple Non-Sarcoma Tumor Cell Lines

To determine whether these sorafenib effects were specific to STS, we assessed other tumor lines. Similar to STS, we detected comparable effects of sorafenib in vitro on human pancreas, breast, and renal cell lines with CSC-promoting effects at low doses but anti-viability effects at doses $\geq 16 \mu\text{M}$ (Figure 2A–F). Additionally, we assessed the effects of sorafenib using other CSC markers since over-reliance on individual CSC markers, like ALDH, has been criticized [33]. For PANC-1, we assessed CD24, CD44, and EpCam since these have been linked with a more specific phenotype for CSCs in pancreas cancer (Figure 2G–I) [36,37]. We saw a similar pattern of an increase in the absolute number of CD24⁺CD44⁺EpCAM⁺ CSCs at low-dose sorafenib ($p \leq 0.01$). As before, at doses $\geq 8 \mu\text{M}$, we observed significant decreases in CSCs, again suggesting dose-dependent effects of sorafenib with CSC expansion at low doses and anti-viability effects at higher doses, further emphasizing that low-dose sorafenib effects on CSC enrichment extend beyond sarcomas and is not restricted to ALDH^{bright} as the CSC marker.




Figure 2. Effects of sorafenib in vitro on non-sarcoma cancer lines. (A–C) Human pancreas cancer (PANC-1) cells, breast cancer (MDA-MB-231) cells, and renal cell cancer (ACHN) cells were cultured with increasing doses of sorafenib. Absolute numbers of viable cells were measured by flow cytometry using 7-AAD to distinguish viable and non-viable cells. (D–F) Human pancreas cancer PANC-1 cells, breast cancer MDA-MB-231 cells, and renal cell cancer ACHN cells were cultured with increasing doses of sorafenib, and ALDH^{bright} cells were measured by flow cytometry using the ALDEFLUORTM assay.

(G) Human pancreas cancer PANC-1 cells were cultured with increasing doses of, and CD24, CD44, and EpCam surface marker expression was measured by flow cytometry. (H,I) Representative flow cytometry staining of PANC-1 cells showing CD24 versus CD44 parent gating with EpCam⁺ cells from the CD24⁺CD44⁺ double positive gate at 2 μ M of sorafenib. All experiments were performed in triplicate. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p \leq 0.0001$ via one-way ANOVA with Tukey's post hoc test.

2.3. Sorafenib Stimulates Proliferation of Human Primary Sarcoma CSCs Ex Vivo

To better represent the tumor heterogeneity of the in vivo microenvironment [38], we evaluated the effects of sorafenib on primary STS tumors. Tumor cells from surgical specimen were processed into single-cell suspension [19,30,39] for ex vivo treatment with increasing doses of sorafenib. Representative H&E photomicrographs are shown (Figure 3A,C). Following ex vivo sorafenib exposure for 24 h, a dedifferentiated liposarcoma specimen showed stable numbers of ALDH^{bright} cells at doses ranging from 0 to 8 μ M, a statistically significant increase in ALDH^{bright} cells at 16 μ M, and a decrease to baseline at 32 μ M (Figure 3B). A leiomyosarcoma primary tumor also showed a significant increase in ALDH^{bright} cells at doses of sorafenib ≥ 16 μ M (Figure 3D). In a third STS patient, we observed an increase in ALDH^{bright} cells from 4.1% to 14.5% after 24 h exposure to 4 μ M of sorafenib ex vivo (Figure 3E) with representative flow cytometry of negative diethylaminobenzaldehyde (DEAB) control and sorafenib populations shown (Figure 3F). Although there was greater variability in the results with primary STS tumors following sorafenib exposure, we nevertheless observed similar effects with increased number and frequency of ALDH^{bright} CSCs in a dose-dependent fashion. Together, these data suggest that sorafenib is also associated with CSC-promoting effects at lower doses in primary STS tumors.




Figure 3. Effects of sorafenib ex vivo on heterogeneous primary sarcoma specimens. (A) Representative H&E stain from human sarcoma patient CCS15-10 showing malignant mesenchymal cells consistent with dedifferentiated liposarcoma at approximately 300 \times magnification. (B) Fresh surgically resected tissue was processed into single-cell suspension and plated ex vivo with indicated doses of sorafenib, then analyzed by flow cytometry for ALDH expression using the ALDEFLUORTM

assay. (C) Representative H&E stain from human sarcoma patient CCS15-12 showing malignant spindle cells consistent with leiomyosarcoma at approximately 300 \times magnification. (D) Fresh surgically resected tissue was processed into single-cell suspension and plated *ex vivo* with indicated doses of sorafenib, then analyzed by flow cytometry for ALDH expression using the ALDEFLUOR™ assay. (E) Sarcoma patient SA-0982 underwent surgical resection, and fresh tumor tissue was processed into a single-cell suspension and plated overnight with sorafenib at 4 μ M compared to diethylaminobenzaldehyde (DEAB) control. Samples were then analyzed for ALDH expression by flow cytometry using the ALDEFLUOR™ assay. (F) Representative flow cytometry staining of ALDH^{bright} cells comparing DEAB control (left) to sorafenib-treated cells (right). **** $p \leq 0.0001$ via one-way ANOVA with Tukey's post hoc test compared to dose level 0.

2.4. Low-Dose Sorafenib Promotes the CSC Phenotype In Vitro and In Vivo

We next sought to determine the impact of low-dose sorafenib exposure on the stem-like behavior of sarcoma CSCs *in vitro* by colony forming unit (CFU) evaluation. Exposure of A673, SK-LMS, and SW982 sarcoma lines to 4 μ M sorafenib significantly increased CFU formation in all three cell lines ($p \leq 0.01$), while pazopanib pre-treatment had no effect (Figure 4A–C). We then assessed the effect of sorafenib pre-treatment on *in vivo* xenograft formation. As shown in Figure 4D, 48 h pre-treatment of A673 cells with 4 μ M sorafenib prior to implantation in NSG mice led to more rapid tumor growth *in vivo* in sorafenib-treated cells with approximately 10-day shorter median survival ($p = 0.05$, Figure 4E). Overall, these data indicate that exposure of sarcoma cells to low-dose sorafenib *in vitro* increases their stem-like behavior as evidenced by increased CFUs *in vitro* and xenograft growth *in vivo*, both of which are associated with the CSC phenotype.




Figure 4. Functional effects of low-dose sorafenib. (A–C) A673 Ewing's sarcoma cells, SK-LMS leiomyosarcoma cells, and SW982 synovial sarcoma cells were cultured overnight with 4 μ M of sorafenib, pazopanib, or vehicle and then plated in soft agar plates for growth in non-adherent culture conditions. Colony forming units were counted and scored. (D) Schema shows experimental design for *in vivo* assessment of tumor growth following sorafenib incubation *in vitro*. Sarcoma cells were incubated with and without low-dose sorafenib for 48 h, subcutaneously injected into the flanks of NSG mice and allowed to form tumors. Tumor growth was measured, and survival was determined according to humane endpoints. (E) Mice pre-treated with low-dose sorafenib prior to tumor implantation had a significantly shorter survival time compared to placebo-treated mice ($p = 0.05$, by log-rank test). An *in vivo* experiment was performed twice. *In vitro* experiments were performed in triplicate. * $p < 0.05$, ** $p < 0.01$ via one-way ANOVA with Tukey's post hoc test.

2.5. ALDH^{bright} A673 Cells Expand after Low-Dose Sorafenib while ALDH^{dim} Cells Do Not

To better assess the specific effects on CSCs versus non-CSCs, we evaluated the effects of sorafenib treatment on sorted ALDH^{bright} and ALDH^{dim} A673 populations. Sorted cells were cultured in sorafenib 4 μ M or vehicle (Figure 5A) for 48 h. As shown in Figure 5B,C, we observed that the ALDH^{bright} cells increased significantly in both frequency and numbers when exposed to low-dose sorafenib compared to ALDH^{dim} cells. Sorted ALDH^{bright} cells gave rise to both ALDH^{bright} and ALDH^{dim} cells, while sorted ALDH^{dim} cells gave rise to essentially all ALDH^{dim} cells. We also observed that the anti-viability effects of low-dose sorafenib (4 μ M) significantly impacted the frequency and absolute numbers of ALDH^{dim} cells while there was no significant anti-viability effect of 4 μ M sorafenib on ALDH^{bright} cell frequencies or absolute numbers (Figure 5D,E). In a separate experiment, as shown in the schema in Figure 5F, we assessed in vivo xenograft formation using sorted A673 ALDH^{bright} and ALDH^{dim} cells that were not exposed to sorafenib. The sorted A673 ALDH^{bright} and ALDH^{dim} cells were immediately injected into the opposite hind limbs of NSG mice, confirming the differential ability for in vivo tumor formation between the CSC and non-CSC populations (Figure 5G,H).




Figure 5. Effects of sorafenib on sorted ALDH^{bright} and ALDH^{dim} subpopulations in A673 Ewing's sarcoma cells. (A) Schema depicting a 48 h in vitro experiment. A673 Ewing's sarcoma cells were sorted via fluorescence-activated cell sorting (FACS) into ALDH^{bright} and ALDH^{dim} subpopulations and plated with and without low-dose sorafenib. The number of ALDH^{bright} cells and viable cells were then measured by flow cytometry. (B,C) Percentage and cell numbers of the ALDH^{bright} cells within treated and untreated sorted ALDH^{bright} and ALDH^{dim} subpopulations were measured by flow cytometry using the ALDEFLUORTM assay. (D,E) Percentage and cell numbers of viable cells within treated and untreated sorted ALDH^{bright} and ALDH^{dim} subpopulations were measured by flow cytometry using 7-AAD. (F) Schema depicting an in vivo experiment. A673 Ewing's sarcoma cells were sorted via FACS into ALDH^{bright} and ALDH^{dim} subpopulations without sorafenib exposure and immediately injected subcutaneously into hind limbs of NSG mice. (G) Representative images of xenograft formation after injection of sorted ALDH^{bright} and ALDH^{dim} cells into hind limbs of NSG mice. (H) Mice treated with ALDH^{bright} A673 cells had a larger tumor volume than those treated with ALDH^{dim}. All experiments were performed in triplicate. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ via one-way ANOVA with Tukey's post hoc test.

2.6. Association of ALDH Enrichment with Worse Oncologic Outcomes in Sorafenib/RT-Treated Patients Treated on a Clinical Trial

Given the potential clinical implications of these findings, we evaluated archived STS patient specimens to link our *in vitro* and *in vivo* results with clinical samples. We previously showed that neoadjuvant sorafenib in combination with RT is tolerable with some evidence of activity in locally advanced extremity STS (NCT#00805727) [25]. Using immunohistochemistry (IHC) on archived specimens from this clinical trial (N = 8) and historical control patients treated with neoadjuvant RT alone (N = 13), we sought to evaluate ALDH scores pre- and post neoadjuvant therapy and assess whether ALDH scores were associated with clinical outcomes. As shown in Figure 6A, there was a significant increase in ALDH scores following neoadjuvant therapy among sorafenib patients who developed metastases. In contrast, there was no statistical difference in ALDH scores among RT monotherapy patients who developed metastases versus those who did not (Figure 6B). We observed a strong inverse correlation between increasing fold change in ALDH score and worse MFS ($r = -0.746$, $p = 0.03$, Figure 6C) among sorafenib/RT patients, whereas there was no significant association between increasing fold change in ALDH score and MFS ($r = -0.193$, $p = 0.53$) among STS patients treated with neoadjuvant RT monotherapy (Figure 6D). We further stratified patients by fold change in ALDH score after neoadjuvant therapy, using the median value of five as the cut point, and compared MFS among patients in the respective cohorts (Figure 6E–G). MFS was worse among sorafenib/RT patients with ALDH fold change ≥ 5 compared to those with ALDH fold change < 5 . Given the small cohort, this difference approached but did not reach statistical significance ($p = 0.09$). In contrast, MFS was not different in patients treated with RT alone when stratified by changes in ALDH scores ($p = 0.33$). These data suggest that increased ALDH scores are associated with worse oncological outcomes in STS patients treated with sorafenib/RT whereas a similar pattern was not observed in patients treated with neoadjuvant RT alone.




Figure 6. Outcomes of sorafenib and RT-treated patients. (A,B) Sarcoma patients received treatment of either sorafenib + RT (N = 8) or RT monotherapy (N = 13), and ALDH score was assessed in both groups pre- and post therapy by immunohistochemistry. Patients were stratified by whether they developed metastasis or not, and sorafenib + RT patients who developed metastases had a significant increase in ALDH scores whereas other groups did not. (C,D) Pre- and post-therapy ALDH scores

were used to calculate fold change in ALDH score, and fold change ALDH score was then correlated to metastasis-free survival in sorafenib + RT versus RT monotherapy cohorts. There was a strong and statistically significant negative correlation between increasing ALDH score and metastasis-free survival in sorafenib + RT patients, while there was a weak and insignificant negative correlation between increasing ALDH score and metastasis-free survival in RT monotherapy patients. (E,F) Kaplan–Meier survival analysis shows metastasis-free survival stratified by ALDH fold change score (using median fold change of 5 as the stratification factor) in sorafenib + RT and RT monotherapy cohorts. (G) Representative immunohistochemical staining for ALDH on sarcoma patient tumor tissue at diagnosis (pre) and at surgical resection post neoadjuvant therapy (RT monotherapy versus RT + sorafenib). (H) FACS-sorted A673 ALDH^{bright} cells were exposed to 4 μ M sorafenib or vehicle for 48 h, and multiplex qPCR was performed for expression of cell cycle and proliferative gene transcripts. *PCNA* and *EGFR* expression was significantly increased in sorafenib-treated cells compared to vehicle. (I) Fold change in serum levels of EGF from diagnosis to surgery in sarcoma patients treated with either surgery only, RT monotherapy, or sorafenib + RT. PCR and Luminex assays were performed in duplicates. * $p < 0.05$ via one-way ANOVA with Tukey's post hoc test.

Lastly, we sought to investigate potential mechanistic pathways underlying the association of low-dose sorafenib with CSC expansion and worse clinical outcomes. We again sorted A673 cells to obtain purified ALDH^{bright} populations and exposed them to low-dose sorafenib (4 μ M) or vehicle for 48 h. Using multiplex qPCR for the expression of cell cycle and proliferation genes, we observed a statistically significant upregulation of proliferation markers *PCNA* and *EGFR* in the sorafenib-treated ALDH^{bright} cells (Figure 6H). Given this significant increase in *EGFR*, we evaluated serum growth factors by Luminex Assay from STS patients treated with surgery only, neoadjuvant RT only, and combination RT/sorafenib. Although not statistically significant, we observed an increased fold change in serum epidermal growth factor (EGF) in patients who were treated with sorafenib and RT compared to the other cohorts (Figure 6I), potentially implicating the EGF-EGFR pathway [40].

3. Discussion

Our data show a consistent increase in cells with a CSC phenotype when exposed to low doses of the multi-tyrosine kinase inhibitor sorafenib. These observations were made in sarcoma cell lines, as well as pancreas, breast, and renal cancer cell lines. These results were recapitulated in primary human sarcoma samples and archived specimens from a phase I clinical trial combining sorafenib with RT as neoadjuvant therapy. These data suggest that low-dose sorafenib promotes expansion of a CSC population that appears to have implications for clinical outcomes.

CSCs have been implicated in multiple cancer processes, including repopulation following cytotoxic therapies, epithelial-to-mesenchymal transition, and tumor recurrence after dormancy [41,42]. In aggregate, the evidence suggests that CSCs are a clinically relevant subpopulation of malignant cells in the bulk tumor. These quiescent cells are resistant to standard cancer treatments such as chemotherapy and RT [1–3]. Consequently, targeting CSCs is an unmet need in cancer therapy. From our results, the increase in ALDH^{bright} cells across models implies that low-dose sorafenib has the potential to have the opposite intended effect and supports the hypothesis that low-dose sorafenib increases the frequency of CSCs in heterogeneous tumor populations, especially STS.

A strength of our study was the access to STS samples and archived clinical trial samples, both of which are important in CSC studies since the nature of cell culture in adherent conditions can limit translational relevance. Additionally, we observed that sorted ALDH^{bright} A673 cells expanded and had increased viability when treated with low-dose sorafenib, while ALDH^{dim} A673 cells did not. The increase in ALDH^{bright} cells across models implies that low-dose sorafenib has the potential to have unintended effects besides

anti-viability/anti-proliferative effects. These results also support the theory that low-dose sorafenib may increase the frequency of CSCs in a heterogenous tumor population.

Regarding the mechanism of sorafenib enhancement, we noted that sorafenib-treated A673 cells had an increase in proliferative markers *Ki67*, *PCNA*, and *EGFR* by PCR. We also observed that mice injected with sorafenib-treated cells, compared to cells grown in standard culture conditions, had a significantly shorter survival time in vivo, secondary to tumor progression. This suggests that low-dose sorafenib increases activation and proliferation in CSCs with greater progression of bulk tumor. These data are supported by a recent study investigating BRAf and MEK inhibitors in hepatocellular carcinoma where the authors observed that administration of a low concentration of sorafenib leads to sustained, and in some cases increased, MAPK signaling via B- and CRAf dimerization [43]. MAPK signaling has often been shown to promote tumor progression [44]. While we did not look at MAPK in our analysis, we observed that there was an increase in proliferative markers *EGFR* and *PCNA* by PCR and EGF in serum in patients who received sorafenib/RT, which may enhance the proliferation of tumor cells [45].

Furthermore, the potential for striking differential effects of TKIs on discrete cancer cell populations was highlighted in a case report of a patient with melanoma administered the selective RAF inhibitor vemurafenib. After 11 days of treatment, a previously palpable subcutaneous melanoma tumor regressed, but the patient soon developed progression of a previously occult chronic myelomonocytic leukemia [46]. The acute development and rapid progression of leukemia resolved after cessation of TKI therapy. This study provides a fascinating proof-of-concept demonstration that pharmacological agents can have differential effects on disparate signaling pathways depending on both the cell type and the genetic and epigenetic machinery which can vary in different cellular constituents within the same patient.

Despite our provocative data, it is important to acknowledge the limitations of our study. For example, we lack in-depth data addressing mechanistic insights that cause low-dose sorafenib to increase the number of ALDH^{bright} cells and promote the CSC phenotype. Although our data implicate low-dose sorafenib in increased numbers of CSCs in vitro, which appears to be related to CSC proliferation rather than conversion to a stem-like phenotype, the precise molecular pathways remain unresolved. Similarly, although we observed striking data that patients with greater increases in ALDH expression after treatment with sorafenib on a clinical trial had worse clinical outcomes, pharmacokinetic data are not available for the on-trial patients, and thus it is not possible to show that the higher ALDH scores and worse oncological outcomes are related to low-dose sorafenib in the serum. Since drug absorption and metabolism may be affected by weight, biological sex, age, and other variables, it is possible that patients may be exposed to drug levels in vivo which can have heterogeneous or disparate effects. However, the potential for drug levels to vary across time and tissues in patients further reinforces the relevance of our findings since fluctuations in drug levels may lead to unintended consequences, as our data highlight. Taken together, our data reinforce the potential for differential and sometimes paradoxical effects of cancer therapeutics based on dose and the possibility for these effects to be different among CSC and non-CSC cancer cell populations.

4. Materials and Methods

4.1. Cell Lines

Cancer cell lines (A673 Ewing's sarcoma, SW-982 synovial sarcoma, SK-LMS leiomyosarcoma, PANC-1 pancreas, MDA-MB231 breast, and ACHN renal) were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in recommended tissue culture media as described previously [19,30,39]. Cell line authentication was verified every 6–12 months using short tandem repeat analysis.

4.2. Colony Forming Unit Assay

Soft agar was purchased from BD Biosciences (San Jose, CA, USA) and plated on tissue culture plates from Corning Inc. (Corning, NY, USA) as described previously [47].

4.3. Flow Cytometry and Sorting

ALDEFLUOR™ expression (STEMCELL Technologies, Vancouver, BC, Canada) was detected using commercial kits as described previously [19,30,39] and included FITC fluorescent channel for the detection of ALDH. PE-Cy7 anti-human CD24, Pacific Blue anti-human CD44, and APC-Cy7 anti-human EpCAM antibodies were purchased from BioLegend (San Diego, CA, USA). 7-Aminoactinomycin D (7-AAD) viability dye was used to identify dead cells. All samples were acquired on an LSR Fortessa with HTS (BD Biosciences, San Jose, CA, USA) and analyzed with FlowJo software, version 10.8.1 (Tree Star, Ashland, OR, USA).

4.4. Primary Tumor Samples

Primary STS tumor tissue (CCS15-10, CCS15-12, and SA-0982) was obtained fresh from surgical specimens through the UC Davis Cancer Center Biorepository. Informed consent was obtained from all patients on an Institutional Review Board-approved protocol. Tumor samples were processed into single-cell suspensions for CSC phenotyping and ex vivo exposure to TKIs as described previously [19,30,39,48,49].

4.5. Retrospective Analysis of Clinical Trial

Results from a phase I trial of neoadjuvant radiotherapy plus sorafenib for patients with locally advanced STS of the extremity and body wall were reported previously (Clinical Trial Information: NCT#00805727) [25]. Here, clinical outcomes were reanalyzed with respect to ALDH staining on archived tumor samples, with further details in Supplemental Methods.

4.6. In Vivo Experiments

Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice aged 6–8 weeks were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice were housed under specific pathogen-free conditions in AAALAC-approved vivarium. Briefly, 1×10^4 sorted A673 ALDH^{bright} and ALDH^{dim} cells were immediately injected subcutaneously into the contralateral hind limbs of NSG mice (within 60 min of cell sorting) and tumor growth was measured. In separate experiments, A673 cells were treated with 4 μ M sorafenib or vehicle for 48 h and then injected subcutaneously into the flanks of NSG mice. Animals were monitored for tumor growth and survival using humane endpoints. All experimental protocols were approved by the UC Davis Institutional Animal Care and Use Committee. The study is reported in accordance with ARRIVE guidelines.

4.7. H&E Staining and Immunohistochemistry

Archived tumor samples were stained for ALDH1 (BD Transduction Laboratories, San Jose, CA, USA) as described previously [39,50]. H-scores were determined in a blinded fashion (MAD).

4.8. Multiplex qRT-PCR

RNA was extracted from A673 ALDH^{bright} cells that were treated with 4 μ M sorafenib using RNeasy Mini kits (Qiagen, Germantown, MD, USA,) according to manufacturer's protocol. The RNA was then reverse transcribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems (Vilnius, Lithuania). Gene-specific primers were designed using Primer-BLAST. Quantitative real time-PCR was performed using the RT2 SYBR Green Mastermix (Qiagen, Germantown, MD, USA) by way of the StepOnePlus™ Real-Time PCR system (Applied Biosystems, Vilnius, Lithuania). RNA amplification and analysis were performed as described previously [39].

4.9. Luminex Assay

Multiplex analysis using R&D Luminex technology was used to determine plasma levels of growth and angiogenic factors before and after treatment for patients as indicated. Samples were measured in duplicates. Additional details regarding reagents and resources used can be found in Supplementary Table S1.

4.10. Statistics

Summary statistics were reported as mean \pm standard error or median (range) where appropriate. Categorical variables were compared using a chi-squared test. Parametric and non-parametric statistics were used as indicated. For comparison of more than 2 groups, statistical significance was determined using a one-way ANOVA followed by a Bonferroni multiple-group comparison test. Survival curves were evaluated using the Kaplan–Meier method. ALDH scores before and after treatment were analyzed using the two-sided paired *t*-test. Statistical analyses were performed using Graph-Pad Prism 8. Significance was set at $p < 0.05$.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms25063351/s1>.

Author Contributions: E.A., I.R.S., J.S.C. and R.J.C. performed in vitro experiments. E.A., I.R.S., J.S.C. and R.J.C. performed in vivo experiments. E.A., J.S.C. and R.J.C. performed ex vivo analysis of human primary sarcomas. M.A.D. evaluated histopathology and immunohistochemical staining. S.M.C., K.R.I., S.J.J., E.A., I.R.S., L.E.F., A.M.M., W.J.M. and R.J.C. participated in the design of the study and assisted with the statistical analysis. E.A., A.M.M., W.J.M. and R.J.C. conceived the study, participated in its design, and supervised progress. S.M.C., K.R.I., S.J.J., L.E.F., I.R.S. and R.J.C. wrote the manuscript. All authors provided critical reviews and approved the final manuscript. S.M.C. and K.R.I. contributed equally to this work. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by funding from the National Institutes of Health (UC Davis Paul Calabresi K12 Career Development Award NIH 1K12CA138464-01A2 (R.J.C.), the National Institute for Health/National Cancer Institute grant R01 CA189209 (W.J.M.), the Sarcoma Foundation of America (R.J.C.), the Society for Surgical Oncology Clinical Investigator Award (R.J.C.), and the University of California Coordinating Committee for Cancer Control (R.J.C.). We also thank Regina Gandour-Edwards, Irmgard Feldman, and Ramona Clarke from the Biorepository Core Facility at the University of California Davis Comprehensive Cancer Center which also receives funding from the National Cancer Institute for support with the acquisition and evaluation of human specimens. This work was also supported in part by funds from the UC Davis Comprehensive Cancer Center and the University of California Davis Flow Cytometry Shared Resource Laboratory with funding from the NCI P30 CA093373 (Cancer Center), and S10 OD018223 (Astrios Cell Sorter), and S10 RR 026825 (Fortessa Cytometer) grants, with technical assistance from Bridget McLaughlin and Jonathan Van Dyke.

Institutional Review Board Statement: All experiments involving human studies were approved by the Institutional Review Board at the University of California, Davis, School of Medicine (# 200816465-3 (sorafenib), # 276403-9 (tissue collection for CCS15), and # 484670-4 (IHC)). All experiments involving mouse models were approved by the Institutional Animal Care and Use Committee at the University of California, Davis, School of Medicine (IACUC# 17861). All methods are in accordance with relevant institutional guidelines and regulations.

Informed Consent Statement: Informed consent was obtained from all patients before tissue procurement under the auspices of the Institutional Review Board of UC Davis.

Data Availability Statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

References

1. Arnold, C.R.; Mangesius, J.; Skvortsova, I.-I.; Ganswindt, U. The Role of Cancer Stem Cells in Radiation Resistance. *Front. Oncol.* **2020**, *10*, 164. [[CrossRef](#)] [[PubMed](#)]
2. Dick, J.E. Stem cell concepts renew cancer research. *Blood* **2008**, *112*, 4793–4807. [[CrossRef](#)]
3. Sukowati, C.H.C. Heterogeneity of Hepatic Cancer Stem Cells. *Adv. Exp. Med. Biol.* **2019**, *1139*, 59–81.
4. Najafi, M.; Mortezaee, K.; Majidpoor, J. Cancer stem cell (CSC) resistance drivers. *Life Sci.* **2019**, *234*, 116781. [[CrossRef](#)]
5. Phi, L.T.H.; Sari, I.N.; Yang, Y.-G.; Lee, S.-H.; Jun, N.; Kim, K.S.; Lee, Y.K.; Kwon, H.Y. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. *Stem Cells Int.* **2018**, *2018*, 5416923. [[CrossRef](#)] [[PubMed](#)]
6. Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. *Nat. Rev. Clin. Oncol.* **2017**, *14*, 611–629. [[CrossRef](#)]
7. Eppert, K.; Takenaka, K.; Lechman, E.R.; Waldron, L.; Nilsson, B.; van Galen, P.; Metzeler, K.H.; Poepl, A.; Ling, V.; Beyene, J.; et al. Stem cell gene expression programs influence clinical outcome in human leukemia. *Nat. Med.* **2011**, *17*, 1086–1093. [[CrossRef](#)] [[PubMed](#)]
8. Lathia, J.; Liu, H.; Matei, D. The Clinical Impact of Cancer Stem Cells. *Oncologist* **2020**, *25*, 123–131. [[CrossRef](#)]
9. Lee, T.K.-W.; Guan, X.-Y.; Ma, S. Cancer stem cells in hepatocellular carcinoma—From origin to clinical implications. *Nat. Rev. Gastroenterol. Hepatol.* **2022**, *19*, 26–44. [[CrossRef](#)]
10. French, R.; Pauklin, S. Epigenetic regulation of cancer stem cell formation and maintenance. *Int. J. Cancer* **2021**, *148*, 2884–2897. [[CrossRef](#)]
11. Butti, R.; Gunasekaran, V.P.; Kumar, T.V.; Banerjee, P.; Kundu, G.C. Breast cancer stem cells: Biology and therapeutic implications. *Int. J. Biochem. Cell Biol.* **2019**, *107*, 38–52. [[CrossRef](#)] [[PubMed](#)]
12. Corrò, C.; Moch, H. Biomarker discovery for renal cancer stem cells. *J. Pathol. Clin. Res.* **2018**, *4*, 3–18. [[CrossRef](#)]
13. He, A.; Qi, W.; Huang, Y.; Feng, T.; Chen, J.; Sun, Y.; Shen, Z.; Yao, Y. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study. *Exp. Ther. Med.* **2012**, *4*, 435–441. [[CrossRef](#)]
14. Rasheed, Z.A.; Matsui, W. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. *J. Gastroenterol. Hepatol.* **2012**, *27*, 15–18. [[CrossRef](#)] [[PubMed](#)]
15. Dontu, G.; Jackson, K.W.; McNicholas, E.; Kawamura, M.J.; Abdallah, W.M.; Wicha, M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. *Breast Cancer Res.* **2004**, *6*, R605–R615. [[CrossRef](#)]
16. Park, D.M.; Jung, J.; Masjkur, J.; Makrogkikas, S.; Ebermann, D.; Saha, S.; Rogliano, R.; Paolillo, N.; Pacioni, S.; McKay, R.D.; et al. Hes3 regulates cell number in cultures from glioblastoma multiforme with stem cell characteristics. *Sci. Rep.* **2013**, *3*, 1095. [[CrossRef](#)] [[PubMed](#)]
17. Sullivan, J.P.; Spinola, M.; Dodge, M.; Raso, M.G.; Behrens, C.; Gao, B.; Schuster, K.; Shao, C.; Larsen, J.E.; Sullivan, L.A.; et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on Notch signaling. *Cancer Res.* **2010**, *70*, 9937–9948. [[CrossRef](#)]
18. Yang, L.; Xie, G.; Fan, Q.; Xie, J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. *Oncogene* **2010**, *29*, 469–481. [[CrossRef](#)]
19. Canter, R.J.; Ames, E.; Mac, S.; Grossenbacher, S.K.; Chen, M.; Li, C.-S.; Borys, D.; Smith, R.C.; Tellez, J.; Sayers, T.J.; et al. Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. *BMC Cancer* **2014**, *14*, 756. [[CrossRef](#)]
20. Chaft, J.E.; Oxnard, G.R.; Sima, C.S.; Kris, M.G.; Miller, V.A.; Riely, G.J. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib—Implications for clinical trial design. *Clin. Cancer Res.* **2011**, *17*, 6298–6303. [[CrossRef](#)]
21. Shien, K.; Toyooka, S.; Yamamoto, H.; Soh, J.; Jida, M.; Thu, K.L.; Hashida, S.; Maki, Y.; Ichihara, E.; Asano, H.; et al. Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells. *Cancer Res.* **2013**, *73*, 3051–3061. [[CrossRef](#)]
22. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res.* **2004**, *64*, 7099–7109. [[CrossRef](#)] [[PubMed](#)]
23. Hasskarl, J. Sorafenib: Targeting multiple tyrosine kinases in cancer. *Recent Results Cancer Res.* **2014**, *201*, 145–164.
24. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; De Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in advanced hepatocellular carcinoma. *N. Engl. J. Med.* **2008**, *359*, 378–390. [[CrossRef](#)] [[PubMed](#)]
25. Canter, R.J.; Borys, D.; Olusanya, A.; Li, C.-S.; Lee, L.-Y.; Boutin, R.D.; Christensen, S.D.; Tamurian, R.M.; Monjazeb, A.M. Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. *Ann. Surg. Oncol.* **2014**, *21*, 1616–1623. [[CrossRef](#)] [[PubMed](#)]
26. Cesne, A.L.; Bauer, S.; Demetri, G.D.; Han, G.; Dezzani, L.; Ahmad, Q.; Blay, J.Y.; Judson, I.; Schöffski, P.; Aglietta, M.; et al. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. *BMC Cancer* **2019**, *19*, 794. [[CrossRef](#)] [[PubMed](#)]
27. Mukherjee, N.; Lambert, K.A.; Norris, D.A.; Shellman, Y.G. Enrichment of Melanoma Stem-Like Cells via Sphere Assays. *Methods Mol. Biol.* **2021**, *2265*, 185–199. [[PubMed](#)]
28. Schatton, T.; Frank, M.H. The In Vitro Spheroid Melanoma Cell Culture Assay: Cues on Tumor Initiation? *J. Investig. Dermatol.* **2010**, *130*, 1769–1771. [[CrossRef](#)]

29. Schatton, T.; Frank, N.Y.; Frank, M.H. Identification and targeting of cancer stem cells. *Bioessays* **2009**, *31*, 1038–1049. [[CrossRef](#)]
30. Ames, E.; Canter, R.J.; Grossenbacher, S.K.; Mac, S.; Chen, M.; Smith, R.C.; Hagino, T.; Perez-Cunningham, J.; Sckisel, G.D.; Urayama, S.; et al. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. *J. Immunol.* **2015**, *195*, 4010–4019. [[CrossRef](#)]
31. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* **2007**, *1*, 555–567. [[CrossRef](#)] [[PubMed](#)]
32. Karimi-Busheri, F.; Rasouli-Nia, A.; Zadorozhny, V.; Fakhrai, H. CD24+/CD38- as new prognostic marker for non-small cell lung cancer. *Multidiscip. Respir. Med.* **2013**, *8*, 65. [[CrossRef](#)] [[PubMed](#)]
33. Mohan, A.; Rajan, R.R.; Mohan, G.; Puthenveetil, P.K.; Maliekal, T.T. Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells. *Front. Cell Dev. Biol.* **2021**, *9*, 668851. [[CrossRef](#)] [[PubMed](#)]
34. Jaggupilli, A.; Elkord, E. Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity. *Clin. Dev. Immunol.* **2012**, *2012*, 708036. [[CrossRef](#)] [[PubMed](#)]
35. Marcato, P.; Dean, C.A.; Giacomantonio, C.A.; Lee, P.W. Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. *Cell Cycle* **2011**, *10*, 1378–1384. [[CrossRef](#)]
36. Hiraga, T.; Ito, S.; Nakamura, H. EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation. *Int. J. Cancer* **2016**, *138*, 1698–1708. [[CrossRef](#)] [[PubMed](#)]
37. Li, W.; Ma, H.; Zhang, J.; Zhu, L.; Wang, C.; Yang, Y. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. *Sci. Rep.* **2017**, *7*, 13856. [[CrossRef](#)] [[PubMed](#)]
38. Sharifnia, T.; Hong, A.L.; Painter, C.A.; Boehm, J.S. Emerging Opportunities for Target Discovery in Rare Cancers. *Cell Chem. Biol.* **2017**, *24*, 1075–1091. [[CrossRef](#)]
39. Ames, R.E.; Canter, R.J.; Grossenbacher, S.K.; Mac, S.; Smith, R.C.; Monjazebe, A.M.; Chen, M.; Murphy, W.J. Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. *OncolImmunology* **2015**, *4*, e1036212. [[CrossRef](#)]
40. Feng, Y.; Dai, X.; Li, X.; Wang, H.; Liu, J.; Zhang, J.; Du, Y.; Xia, L. EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. *Cell Prolif.* **2012**, *45*, 413–419. [[CrossRef](#)]
41. Batlle, E.; Clevers, H. Cancer stem cells revisited. *Nat. Med.* **2017**, *23*, 1124–1134. [[CrossRef](#)] [[PubMed](#)]
42. Ghajar, C.M. Metastasis prevention by targeting the dormant niche. *Nat. Rev. Cancer* **2015**, *15*, 238–247. [[CrossRef](#)] [[PubMed](#)]
43. Breunig, C.; Mueller, B.J.; Umansky, L.; Wahl, K.; Hoffmann, K.; Lehner, F.; Manns, M.P.; Bantel, H.; Falk, C.S. BRAF and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma. *Clin. Cancer Res.* **2014**, *20*, 2410–2423. [[CrossRef](#)] [[PubMed](#)]
44. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. *Oncogene* **2007**, *26*, 3279–3290. [[CrossRef](#)] [[PubMed](#)]
45. Wang, S.-C.; Nakajima, Y.; Yu, Y.-L.; Xia, W.; Chen, C.-T.; Yang, C.-C.; McIntush, E.W.; Li, L.-Y.; Hawke, D.H.; Kobayashi, R.; et al. Tyrosine phosphorylation controls PCNA function through protein stability. *Nature* **2006**, *8*, 1359–1368. [[CrossRef](#)] [[PubMed](#)]
46. Callahan, M.K.; Rampal, R.; Harding, J.J.; Klimek, V.M.; Chung, Y.R.; Merghoub, T.; Wolchok, J.D.; Solit, D.B.; Rosen, N.; Abdel-Wahab, O.; et al. Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. *N. Engl. J. Med.* **2012**, *367*, 2316–2321. [[CrossRef](#)]
47. Rajendran, V.; Jain, M.V. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells. In *Cancer Stem Cells: Methods and Protocols*; Papaccio, G., Desiderio, V., Eds.; Springer: New York, NY, USA, 2018; pp. 89–95. [[CrossRef](#)]
48. Cruz, S.M.; Sholevar, C.J.; Judge, S.J.; Darrow, M.A.; Iranpur, K.R.; Farley, L.E.; Lammers, M.; Razmara, A.M.; Dunai, C.; Gingrich, A.A.; et al. Intratumoral NKp46+ natural killer cells are spatially distanced from T and MHC-I+ cells with prognostic implications in soft tissue sarcoma. *Front. Immunol.* **2023**, *14*, 1230534. [[CrossRef](#)]
49. Judge, S.J.; Darrow, M.A.; Thorpe, S.W.; Gingrich, A.A.; O'Donnell, E.F.; Bellini, A.R.; Sturgill, I.R.; Vick, L.V.; Dunai, C.; Stoffel, K.M.; et al. Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. *J. Immunother. Cancer* **2020**, *8*, e001355. [[CrossRef](#)]
50. Henderson, T.; Chen, M.; Darrow, M.A.; Li, C.-S.; Chiu, C.-L.; Monjazebe, A.M.; Murphy, W.J.; Canter, R.J. Alterations in Cancer Stem Cell Marker CD44 Expression Predict Oncologic Outcome in Soft Tissue Sarcomas. *J. Surg. Res.* **2018**, *223*, 207–214. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.